Patents Assigned to Theaprin Pharmaceuticals Inc.
  • COCRYSTAL ANTIOXIDANTS OF PROTOCATECHUIC ACID WITH L-THEANINE FOR THE TREATMENT OF OXIDATIVE STRESS AND INFLAMMATORY CONDITIONS
    Publication number: 20230201147
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 29, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • COCRYSTAL ANTIOXIDANTS OF PROTOCATECHUIC ACID WITH L-THEANINE FOR THE TREATMENT OF OXIDATIVE STRESS AND INFLAMMATORY CONDITIONS
    Publication number: 20230201152
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 29, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • COCRYSTAL ANTIOXIDANTS OF PROTOCATECHUIC ACID WITH L-THEANINE FOR THE TREATMENT OF OXIDATIVE STRESS AND INFLAMMATORY CONDITIONS
    Publication number: 20230111210
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE, AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
    Publication number: 20230110872
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE ,AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
    Publication number: 20230115710
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20210177758
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 17, 2021
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Harry G. BRITTAIN, Philip V. FELICE
  • SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE, AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
    Publication number: 20200101010
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 2, 2020
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine
    Patent number: 10376464
    Abstract: Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 13, 2019
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20180064649
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: February 29, 2016
    Publication date: March 8, 2018
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. BRITTAIN, Philip V. FELICE
  • Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine
    Patent number: 9896411
    Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 20, 2018
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • CHARACTERIZATION OF THE COCRYSTAL PRODUCTS FORMED BY METOPROLOL AND DABIGATRAN BASES WITH L-THEANINE
    Publication number: 20170143838
    Abstract: Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: October 3, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • CHARACTERIZATION OF THE COCRYSTAL PRODUCTS FORMED BY METOPROLOL AND DABIGATRAN BASES WITH L-THEANINE
    Publication number: 20170143648
    Abstract: Methods of treating and preventing conditions by employing cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • CHARACTERIZATION OF THE COCRYSTAL PRODUCTS FORMED BY METOPROLOL AND DABIGATRAN BASES WITH L-THEANINE
    Publication number: 20170144964
    Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Platform drug delivery system utilizing crystal engineering and theanine dissolution
    Patent number: 9603939
    Abstract: A method of treating Hodgkin's disease in a subject. The method involves administering to the subject an effective amount of a water-soluble composition which includes a cocrystal composition containing doxorubicin and a theanine enantiomer.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 28, 2017
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Platform drug delivery system utilizing crystal engineering and theanine dissolution
    Patent number: 9603938
    Abstract: A method of making a water-soluble doxorubicin-theanine cocrystal composition. The method includes the steps of providing a quantity of doxorubicin, adding a quantity of a theanine enantiomer to the quantity of doxorubicin to form a mixture of the quantity of doxorubicin and the enantiomer of theanine, wetting the mixture, and grinding the mixture for a length of time sufficient to produce a dried crystalline mass.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: March 28, 2017
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Platform drug delivery system utilizing crystal engineering and theanine dissolution
    Patent number: 9603937
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: March 28, 2017
    Assignee: Theaprin Pharmaceuticals Inc.
    Inventors: Harry G. Brittain, Philip V. Felice
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20160263138
    Abstract: A method of treating Hodgkin's disease in a subject. The method involves administering to the subject an effective amount of a water-soluble composition which includes a cocrystal composition containing doxorubicin and a theanine enantiomer.
    Type: Application
    Filed: April 13, 2016
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20160263224
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: March 9, 2015
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20160263229
    Abstract: A method of making a water-soluble doxorubicin-theanine cocrystal composition. The method includes the steps of providing a quantity of doxorubicin, adding a quantity of a theanine enantiomer to the quantity of doxorubicin to form a mixture of the quantity of doxorubicin and the enantiomer of theanine, wetting the mixture, and grinding the mixture for a length of time sufficient to produce a dried crystalline mass.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
    Patent number: 9289440
    Abstract: A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice